Study design and patient disposition. Parts 4 and 5 were removed by a later protocol amendment (19 May 2016). HL, Hodgkin lymphoma; TEAE, treatment-emergent adverse event. *As of data cutoff (18 August 2017). †Because of septic shock and respiratory failure.